乐普医疗(300003) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥2,749,291,118.03, representing a 64.96% increase compared to ¥1,666,605,604.40 in the same period last year[4] - Net profit attributable to shareholders was ¥726,138,208.52, an increase of 89.17% from ¥383,864,743.91 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥682,553,832.11, up 81.76% from ¥375,534,946.55 in the previous year[4] - Basic earnings per share were ¥0.4052, reflecting an 86.73% increase from ¥0.2170 year-on-year[4] - The net profit for the period was CNY 757.63 million, an increase of 94.60% year-on-year, while the net profit attributable to shareholders was CNY 726.14 million, up 89.17%[12] - The total comprehensive income for the first quarter was CNY 784,223,601.19, compared to CNY 330,309,746.30 in the same period last year, marking an increase of approximately 137.5%[32] Cash Flow - The net cash flow from operating activities reached ¥1,299,360,017.17, a significant increase of 1,133.22% compared to ¥105,363,331.48 in the same period last year[4] - The cash inflow from operating activities reached CNY 3,502,240,342.13, a significant increase from CNY 1,689,168,489.13 in the previous period, representing a growth of approximately 107.5%[36] - The net cash flow from operating activities for the first quarter was CNY 1,299,360,017.17, compared to CNY 105,363,331.48 in the same period last year, indicating a substantial increase of about 1,132.5%[37] - The company's cash and cash equivalents at the end of the period were CNY 3,404.28 million, an increase of CNY 970.31 million, representing a growth rate of 39.86%[14] - The cash inflow from financing activities totaled CNY 721,300,000.00, down from CNY 1,068,006,782.45, representing a decline of approximately 32.5%[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥20,173,767,500.66, an increase of 11.11% from ¥18,156,865,082.22 at the end of the previous year[4] - The total liabilities increased to CNY 8,853,091,898.78 from CNY 7,619,438,633.75 year-over-year, reflecting a growth of approximately 16.2%[26] - The total equity attributable to shareholders of the parent company rose to CNY 10,630,676,886.40, up from CNY 9,872,791,251.61, representing an increase of about 7.7%[26] - The company's long-term borrowings increased to CNY 1,310,250,000.00 from CNY 1,115,216,273.83, representing a rise of about 17.5%[29] - The total current liabilities decreased to CNY 5,759,891,220.09 from CNY 4,811,906,068.20, reflecting a growth of approximately 19.7%[26] Shareholder Information - The top ten shareholders held a combined 56.67% of the company's shares, with the largest shareholder owning 13.52%[7] - The company reported a total of CNY 1,804,581,117.00 in share capital, consistent with prior figures[44] Research and Development - The company has initiated clinical trials for a GLP-1 receptor agonist injection through its subsidiary, indicating ongoing investment in new product development[17] - The company received regulatory approval for 16 in vitro diagnostic reagents, including 11 autoimmune disease markers and 5 diabetes testing products[16] - The company developed the world's first fully biodegradable occluder system, which received a registration acceptance notice from the National Medical Products Administration[16] Operational Stability - The company has not reported any significant changes in its core assets or key personnel during the reporting period, ensuring stability in its operations[18] - The company has not faced any major risk factors or operational difficulties that could adversely affect its future performance[18] - The company has not engaged in any significant mergers or acquisitions during the reporting period, maintaining its current strategic focus[18] Expenses - Research and development expenses amounted to CNY 164,993,416.02, an increase from CNY 127,503,382.52, showing a rise of about 29.3%[34] - Sales expenses increased to CNY 499,996,815.74 from CNY 422,743,418.76, representing a rise of approximately 18.3%[34] - The company’s tax expenses for the quarter were CNY 159,329,492.33, compared to CNY 73,890,216.63 in the previous year, indicating an increase of about 115.5%[34] Other Financial Metrics - The company reported an investment loss of CNY -26,809,277.50, worsening from a loss of CNY -5,980,713.98 in the previous year[34] - Other comprehensive income after tax was CNY 26,594,998.93, contrasting with a loss of CNY -59,012,168.27 in the same period last year[32] - The company received government subsidies amounting to ¥11,696,723.26 during the reporting period[5]